Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

New strategies trying to achieve blood pressure control and consequently reduce cardiovascular risk in resistant hypertensive subjects are promising. In this context, the SGLT2 inhibitor dapagliflozin, not yet investigated in resistant hypertension, arises as a potential drug in order to impact on blood pressure levels, as well as target organ damage and adiposity in this high-risk population.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Campinas, Brazil
• Collaborator: Fundação de Amparo à Pesquisa do Estado de São Paulo
• Treatments: Dapagliflozin; Glyburide

Criteria

Inclusion Criteria:

• Resistant hypertension and type 2 diabetes diagnoses after a 6-month follow-up

• Use of metformin therapy

• Therapy adherence

• Agree to participate in the research protocol and sign the informed consent form

Exclusion Criteria:

• secondary Hypertension

• pseudoresistance hypertension (poor medication adherence and white coat hypertension)

• patients with symptomatic ischemic heart disease, impaired renal function, liver disease and history of stroke, myocardial infarction and peripheral vascular diseases

• pregnancy

• smoking

• autoimmune diseases